Recombinant Human OX40/CD134 protein (Myc Tag, His Tag)

种属

Human

纯度

>95 %, SDS-PAGE

标签

Myc Tag, His Tag

生物活性

EC50: 0.3-1.2 ng/mL

Cat no : Eg0022

Print datasheet

Synonyms

OX40/TNFRSF4, TNFRSF4, ACT35, ACT35 antigen, CD134



产品信息

纯度 >95 %, SDS-PAGE
内毒素 <0.1 EU/μg protein, LAL method
生物活性
Immobilized Human OX40 (Myc tag, His tag) at 2 μg/mL (100 μL/well) can bind Human OX40L (hFc tag) with a linear range of 0.3-1.2 ng/mL.
来源 HEK293-derived Human OX40 protein Leu29-Ala214 (Accession# P43489) with a Myc tag and a His tag at the C-terminus.
基因ID 7293
蛋白编号 P43489
预测分子量 22.5 kDa
SDS-PAGE 38-50 kDa, reducing (R) conditions
组分 Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
复溶 Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
储存条件
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
运输条件 The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

背景信息

CD134 (OX40, TNFRSF4) is a member of the TNFR-superfamily of receptors. Recent evidence indicates that OX40-OX40L coupling is critical for cell survival and proliferation. While OX40 is expressed predominantly on T-lymphocytes early after antigen activation, OX40L is expressed on activated antigen presenting cells and endothelial cells within acute inflammatory environments. The tumour necrosis factor receptor OX40 (CD134) is activated by its cognate ligand OX40L (CD134L, CD252) and functions as a T cell co-stimulatory molecule. OX40 is expressed on activated T cells, and in the mouse at rest on regulatory T cells (Treg). CD134 can interact with TRAF2, TRAF3, and TRAF5. OX40 is an immune checkpoint in cancer and its presence in cancer is a good prognosis, making it a highly relevant target for the development of new immunotherapies.

参考文献:

1.Wu LY. et al. (2020). Exp Neurol. 326:113179. 2.Gough MJ. et al. (2009). Adv Exp Med Biol. 647:94-107. 3.Webb GJ. et al. (2016). Clin Rev Allergy Immunol. 50(3):312-32. 4.Cebada J. et al. (2021). Expert Opin Ther Pat. 31(1):81-90.